Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMethylprednisolone hemisuccinate
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Methylprednisolone hemisuccinate
- Accession Number
- DB14644
- Type
- Small Molecule
- Groups
- Approved
- Description
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Structure
Structure for Methylprednisolone hemisuccinate (DB14644)
- Synonyms
- Methylprednisolone hydrogen succinate
- Methylprednisolone succinate
- Product Ingredients
Ingredient UNII CAS InChI Key Methylprednisolone sodium succinate LEC9GKY20K 2375-03-3 FQISKWAFAHGMGT-SGJOWKDISA-M - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataSolu-Medrol Injection, powder, for solution 40 mg/1mL Intramuscular; Intravenous General Injectables & Vaccines, Inc 2010-04-01 Not applicable US 
Solu-Medrol Powder, for solution 125 mg/1mL Intravenous Remedy Repack 2011-12-15 2015-07-01 US Solu-medrol Injection, powder, for solution 125 mg/2mL Intramuscular; Intravenous Pharmacia and Upjohn Company LLC 1959-04-02 Not applicable US Solu-medrol Injection, powder, for solution 125 mg/2mL Intramuscular; Intravenous REMEDYREPACK INC. 2019-04-15 Not applicable US Solu-medrol Injection, powder, for solution 125 mg/1mL Intramuscular; Intravenous Mesource Pharmaceuticals 2014-07-18 Not applicable US Solu-medrol Injection, powder, for solution 40 mg/1mL Intramuscular; Intravenous Pharmacia and Upjohn Company LLC 1959-04-02 Not applicable US Solu-medrol Injection, powder, for solution 125 mg/2mL Intramuscular; Intravenous A-S Medication Solutions 1959-04-02 Not applicable US Solu-medrol Injection, powder, for solution 125 mg/2mL Intramuscular; Intravenous Nucare Pharmaceuticals,inc. 1959-04-02 Not applicable US Solu-medrol Injection, powder, for solution 40 mg/1mL Intramuscular; Intravenous Physicians Total Care, Inc. 1959-04-02 2012-06-30 US Solu-medrol Injection, powder, for solution 1 g/1mL Intramuscular; Intravenous Pharmacia and Upjohn Company LLC 1959-04-02 Not applicable US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataA-methapred Injection, powder, lyophilized, for solution 125 mg/2mL Intramuscular; Intravenous Hospira, Inc. 2006-10-06 2010-07-01 US A-methapred Injection, powder, lyophilized, for solution 40 mg/1mL Intramuscular; Intravenous Hospira, Inc. 2006-10-06 2010-07-01 US A-methapred Injection, powder, for solution 125 mg/2mL Intramuscular; Intravenous Hospira, Inc. 2009-06-22 2013-05-01 US A-methapred Injection, powder, for solution 40 mg/1mL Intramuscular; Intravenous Hospira, Inc. 2009-07-14 2013-05-01 US Methylprednisolone Sodium Succinate Injection, powder, for solution 1 g/1 Intramuscular; Intravenous Hikma Pharmaceuticals USA Inc. 2016-01-01 Not applicable US Methylprednisolone Sodium Succinate Injection, powder, lyophilized, for solution 40 mg/1mL Intramuscular; Intravenous Sagent Pharmaceuticals 2017-03-15 Not applicable US Methylprednisolone Sodium Succinate Injection, powder, for solution 500 mg/1 Intramuscular; Intravenous Hikma Pharmaceuticals USA Inc. 2016-01-01 Not applicable US Methylprednisolone Sodium Succinate Injection, powder, lyophilized, for solution 1 g/8mL Intramuscular; Intravenous Bedford Pharmaceuticals 2007-03-01 2009-06-30 US Methylprednisolone Sodium Succinate Injection, powder, lyophilized, for solution 125 mg/2mL Intramuscular; Intravenous Fresenius Kabi USA, LLC 2004-11-30 Not applicable US Methylprednisolone Sodium Succinate Injection, powder, lyophilized, for solution 40 mg/1mL Intramuscular; Intravenous Fresenius Kabi USA, LLC 2004-11-30 Not applicable US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Categories
- Adrenal Cortex Hormones
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Central Nervous System Agents
- Compounds used in a research, industrial, or household setting
- Corticosteroids
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strength unknown)
- Cytochrome P-450 CYP3A5 Inducers
- Cytochrome P-450 CYP3A5 Inducers (strength unknown)
- Cytochrome P-450 Enzyme Inducers
- Fused-Ring Compounds
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Neuroprotective Agents
- Pregnadienes
- Pregnadienetriols
- Pregnanes
- Protective Agents
- Steroids
- UNII
- 5GMR90S4KN
- CAS number
- 2921-57-5
- Weight
- Average: 474.55
Monoisotopic: 474.225368055 - Chemical Formula
- C26H34O8
- InChI Key
- IMBXEJJVJRTNOW-XYMSELFBSA-N
- InChI
- InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1
- IUPAC Name
- 4-{2-[(1R,3aS,3bS,5S,9aR,9bS,10S,11aS)-1,10-dihydroxy-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
- SMILES
- [H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Acute Gouty Arthritis
- Ankylosing Spondylitis (AS)
- Berylliosis
- Congenital Adrenal Hyperplasia (CAH)
- Congenital Hypoplastic Anemia
- Dermatomyositis
- Edema of the cerebrum
- Hypercalcemia of Malignancy
- Idiopathic Thrombocytopenic Purpura
- Leukemias
- Malignant Lymphomas
- Multiple sclerosis exacerbation
- Mycosis Fungoides (MF)
- Ophthalmia, Sympathetic
- Pemphigus
- Polymyositis
- Primary adrenocortical insufficiency
- Psoriatic Arthritis
- Pure Red Cell Aplasia
- Refractory Uveitis
- Regional Enteritis
- Rheumatoid Arthritis
- Secondary adrenocortical insufficiency
- Secondary thrombocytopenia
- Severe allergic reaction
- Stevens-Johnson Syndrome
- Systemic Lupus Erythematosus (SLE)
- Temporal Arteritis
- Trichinosis
- Tuberculous Meningitis
- Ulcerative Colitis
- Acquired immune hemolytic anemia
- Acute rheumatic carditis
- Bullous dermatitis
- Disseminated Pulmonary Tuberculosis (TB)
- Exfoliative erythroderma
- Fulminating Pulmonary Tuberculosis
- Idiopathic eosinophilic pneumonias
- Non-suppurative Thyroiditis
- Symptomatic Sarcoidosis
- Associated Therapies
- Pharmacodynamics
Methylprednisolone sodium succinate (the sodium salt of methylprednisolone hemisuccinate) has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity.
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Unlock Additional Data
Additional Data Available
Adverse Effects
Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.
Learn more Additional Data Available
Contraindications
Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.
Learn more Additional Data Available
Blackbox Warnings
Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.
Learn moreInteractions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional Data(R)-warfarin Methylprednisolone hemisuccinate may increase the anticoagulant activities of (R)-warfarin. (S)-Warfarin Methylprednisolone hemisuccinate may increase the anticoagulant activities of (S)-Warfarin. 1-Testosterone The risk or severity of edema formation can be increased when 1-Testosterone is combined with Methylprednisolone hemisuccinate. 1,10-Phenanthroline The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Methylprednisolone hemisuccinate. 16-Bromoepiandrosterone The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Methylprednisolone hemisuccinate. 19-norandrostenedione The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Methylprednisolone hemisuccinate. 1alpha-Hydroxyvitamin D5 The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Methylprednisolone hemisuccinate. 1alpha,24S-Dihydroxyvitamin D2 The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Methylprednisolone hemisuccinate. 2,4-thiazolidinedione The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with 2,4-thiazolidinedione. 4-hydroxycoumarin Methylprednisolone hemisuccinate may increase the anticoagulant activities of 4-hydroxycoumarin. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
References
- General References
- FDA Approved Drug Products: Solu-Medrol (methylprednisolone sodium succinate) for injection [Link]
- External Links
- ChemSpider
- 16034
- ChEBI
- 135765
- ChEMBL
- CHEMBL1201265
- ZINC
- ZINC000003977781
- Wikipedia
- Methylprednisolone
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Injection, powder, for solution Intramuscular; Intravenous 125 mg/2mL Injection, powder, for solution Intramuscular; Intravenous 1 g/1 Injection, powder, for solution Intramuscular; Intravenous 500 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 1 g/16mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 1 g/8mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 125 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 125 mg/2mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 2 g/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 40 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 40 mg/1mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 500 mg/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 500 mg/8mL Injection, powder, lyophilized, for solution Intramuscular; Intravenous 500 mg/4mL Injection, powder, for solution Intracavernous; Intramuscular 40 mg/1 Injection, powder, for solution Intramuscular; Intravenous 1 g/1mL Injection, powder, for solution Intramuscular; Intravenous 1 g/8mL Injection, powder, for solution Intramuscular; Intravenous 125 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 2 g/30.6mL Injection, powder, for solution Intramuscular; Intravenous 40 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 500 mg/1mL Injection, powder, for solution Intramuscular; Intravenous 500 mg/4mL Injection, powder, for solution Intravenous 1 g/1 Injection, powder, lyophilized, for solution Intramuscular; Intravenous 125 mg/1mL Powder, for solution Intravenous 125 mg/1mL Powder, for solution Intramuscular; Intravenous; Rectal - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0264 mg/mL ALOGPS logP 2.43 ALOGPS logP 1.83 ChemAxon logS -4.2 ALOGPS pKa (Strongest Acidic) 3.66 ChemAxon pKa (Strongest Basic) -2.9 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 7 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 138.2 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 123.09 m3·mol-1 ChemAxon Polarizability 49.87 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [PubMed:20482443]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [PubMed:20482443]
Drug created on September 01, 2018 15:25 / Updated on May 16, 2020 15:55
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates